Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Certican Short-Term Renal Safety Study Suggested By Panel

Executive Summary

A short-term renal toxicity study establishing the safety of Novartis' Certican with lower doses of cyclosporine could sway members of FDA's Cardiovascular & Renal Drugs Advisory Committee to recommend approval of the immunosuppressant in heart transplantation

You may also be interested in...



Approval Of Novartis' Everolimus Could Mean mTOR Inhibitor Class REMS

The likely approval of Novartis' everolimus for prevention of kidney transplant rejection could bring with it safety labeling updates and Risk Evaluation and Mitigation Strategies for all drugs in the mTOR inhibitor class

Approval Of Novartis' Everolimus Could Mean mTOR Inhibitor Class REMS

The likely approval of Novartis' everolimus for prevention of kidney transplant rejection could bring with it safety labeling updates and Risk Evaluation and Mitigation Strategies for all drugs in the mTOR inhibitor class

Panel Recommends Novartis' Kidney Transplant Drug Certican

Taking the panel's previous advice to demonstrate everolimus' efficacy with lower doses of cyclosporine is what gained the committee endorsement Dec. 7.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel